Medical Devices Startups

Sinaptica develops a noninvasive, personalized closed-loop rTMS-EEG neuromodulation therapy for Alzheimer's disease that stimulates the precuneus and Default Mode Network to slow disease progression. The therapy targets cognition, function, and behavior and is calibrated per patient using MRI and TMS-evoked potential data.

5 investors

Siphox Health develops early diagnostic testing technology to detect and manage chronic diseases at home, delivered as a painless 5-minute test that enables frequent monitoring. The company targets the U.S. healthcare system to reduce the health and economic burden of chronic disease.

5 investors

Step Pharma develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor in clinical development as a targeted oncology therapy for blood cancers such as lymphoma and essential thrombocythaemia as well as solid tumours including ovarian cancer. The company focuses on CTPS1 inhibition for cancer treatment.

5 investors

Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.

5 investors

Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline. The company serves patients with motor impairment and cognitive decline using a minimally invasive approach inspired by cardiac interventional procedures.

5 investors

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target. Its lead program targets TAG72, a non-internalizing marker expressed in difficult-to-treat solid tumors, aiming to expand ADC target scope and therapeutic window.

5 investors

TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis. Its lead compound, TGD001, is a targeted thrombolytic in preclinical development for thrombotic disorders including immune thrombotic thrombocytopenic purpura (iTTP) and acute ischemic stroke.

5 investors

Tarsus Rx is a pharmaceutical company developing treatments for diseases with high unmet need, with a lead product XDEMVY (lotilaner ophthalmic solution) approved by the FDA for Demodex blepharitis. It maintains a pipeline of therapies targeting large disease categories with limited treatment options.

5 investors

ThinkSono makes Guidance, an AI software that uses real-time guidance to help non-ultrasound-trained healthcare professionals perform compression ultrasound scans to detect deep vein thrombosis (DVT) at the point of care. The product is a CE Class IIb medical device marketed to hospitals and healthcare providers in the EU and UK.

5 investors

Trially uses AI and data science to match patients with clinical trials and accelerate trial recruitment. The platform targets research sites and trial sponsors seeking to reduce screening time and trial delays through HIPAA-compliant patient data analysis.

5 investors

TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation. The company runs clinical studies across Europe and the US targeting structural heart institutions and cardiac patients.

5 investors

SonarMD provides a care management platform for chronic diseases, starting with gastroenterology, that combines AI technology with human support to detect clinical deterioration early and help specialists intervene before emergencies. It serves health plans and provider partners in a value-based care model aimed at reducing healthcare costs.

5 investors

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.

5 investors

Varinos develops and provides genetic testing services applying genome technology, including a uterine microbiome (endometrial flora) test used in fertility and reproductive medicine. The company serves patients and clinics addressing infertility.

5 investors

Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.

5 investors

ViewsML applies AI to support the development and delivery of precision medicines, including virtual IHC technology for pathology. It operates in the AI-driven healthcare and diagnostics space.

5 investors

Vocxi Health develops MyBreathPrint, a noninvasive breath-analysis system that uses a sensor array to detect volatile organic compounds at parts-per-billion levels and connect them to disease patterns, with an initial focus on early lung cancer detection. Results are uploaded to a cloud platform and delivered to a physician for analysis, intended for use in doctors' offices and eventually at home.

5 investors

Wearlinq develops the eWave, a wireless, FDA-cleared 6-lead continuous ECG cardiac monitor with a patient smartphone app and the LiveLinq platform for clinicians to review ECG waveforms and reports. Its products serve cardiologists and clinical teams for continuous cardiac monitoring and diagnostic reporting.

5 investors

Zerigo Health develops technology-driven digital therapeutics and care solutions for individuals living with chronic skin conditions. It combines device-based and data-driven approaches to support patient-centered care.

5 investors

Wellumio develops axana®, a portable, energy-efficient MRI system based on its Pulsed Gradient Free Mapping (PGFM) technology, designed to detect acute stroke quickly in front-line care settings. The product targets stroke diagnostics and brain imaging workflows in medical and critical care environments.

5 investors

XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.

5 investors

YourChoice Therapeutics develops YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials that works by blocking a receptor essential for sperm production. The company targets men seeking an alternative to condoms or vasectomy.

5 investors

Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.

5 investors

ARMR Systems develops a wearable vascular clamp system for rapid hemorrhage control in trauma situations where medical help is not immediately available. The technology is designed for soldiers, first responders, and emergency personnel to stop life-threatening bleeding without advanced medical training.

4 investors